63 results
8-K
EX-99.1
BCDA
BioCardia Inc.
19 Dec 23
Other Events
7:00am
patients treated with culture expanded MSCs or dedicated controls using the Helix delivery system with no observed treatment emergent serious adverse events
424B5
BCDA
BioCardia Inc.
17 Nov 23
Prospectus supplement for primary offering
5:25pm
Our second therapeutic platform is our investigational culture expanded bone marrow derived allogenic or "off the shelf" mesenchymal cell therapy
8-K
EX-99.1
BCDA
BioCardia Inc.
9 Aug 23
Biocardia Reports Second Quarter 2023 Business Highlights and Financial Results
4:08pm
) in ischemic heart failure using the Company’s proprietary Helix™ delivery system encompassing 93 patients treated with culture expanded MSCs
424B5
rr1u3afkl
22 Jun 23
Prospectus supplement for primary offering
8:33am
8-K
EX-99.1
u883 01hpvwne
6 Dec 22
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
7:01am
8-K
EX-99.1
p4f g5qo9
9 Nov 22
Biocardia Reports Third Quarter 2022 Business Highlights and Financial Results
4:07pm
8-K
EX-99.1
48yyz
10 Aug 22
Biocardia Reports Second Quarter 2022 Business Highlights and Financial Results
4:06pm
8-K
EX-99.1
rxt9ag5v ohmip3h98p
11 May 22
Biocardia Reports First Quarter 2022 Business Highlights and Financial Results
4:06pm
424B5
kifgr4r4ljd wmv8
12 Apr 22
Prospectus supplement for primary offering
8:01am
8-K
EX-99.1
3a9j7u2i90o7 t6ucp
29 Mar 22
Biocardia Reports 2021 Financial Results and Recent Business Highlights
4:07pm